Insulin-like growth factor pathway genetic polymorphisms, circulating igf1 and IGFBP3, and prostate cancer survival

Journal of the National Cancer Institute

Volumn 106, Issue 5, 2014, Pages

  Cao, Yin ^a,b   Lindström, Sara ^a   Schumacher, Fredrick ^c   Stevens, Victoria L ^d   Albanes, Demetrius ^e   Berndt, Sonja I ^e   Boeing, Heiner ^f   Bas Bueno De Mesquita, H ^g,h   Canzian, Federico ⁱ   Chamosa, Saioa ^j   Chanock, Stephen J ^e,k   Diver, W Ryan ^d   Gapstur, Susan M ^d   Gaziano, J Michael ^l,m   Giovannucci, Edward L ^a,b   Haiman, Christopher A ^c   Henderson, Brian ^c   Johansson, Mattias ^c   Marchand, Loïc Le ^p   Palli, Domenico ^q   Rosner, Bernard ^a   Siddiq, Afshan ^r   Stampfer, Meir ^a   Stram, Daniel O ^c   Tamimi, Rulla ^a,b   Travis, Ruth C ^s   Trichopoulos, Dimitrios ^a,t,u   Willett, Walter C ^a   Yeager, Meredith ^e,k   Kraft, Peter ^a   Hsing, Ann W ^v   Pollak, Michael ^w   Lin, Xihong ^a   Ma, Jing ^a,b,n,o   more..

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d AMERICAN CANCER SOCIETY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^g NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^j BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^k FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁿ INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^o UMEÅ UNIVERSITY   (Sweden)

^p UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^q CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^r IMPERIAL COLLEGE LONDON   (United Kingdom)

^s UNIVERSITY OF OXFORD   (United Kingdom)

^t BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^u HELLENIC HEALTH FOUNDATION   (Greece)

^v STANFORD CANCER INSTITUTE   (United States)

^w MCGILL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SOMATOMEDIN; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C; IGF2 AS PROTEIN, HUMAN; IGF2-AS PROTEIN, HUMAN; IGFBP3 PROTEIN, HUMAN; PROTEIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR SUBTYPE 2, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; KERNEL METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CANCER GRADING; CANCER STAGING; CASE CONTROL STUDY; EUROPE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; GERMLINE MUTATION; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY (TOPIC); PROSTATE TUMOR; SIGNAL TRANSDUCTION; UNITED STATES; ALLELE; CANCER PATIENT; GENETIC ASSOCIATION; GENETIC RISK; HAZARD RATIO;

AGED; CASE-CONTROL STUDIES; EUROPE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GERM-LINE MUTATION; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEOPLASM GRADING; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; PROTEINS; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84905173639     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju218     Document Type: Article

References (35)

1. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915-928.
2. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol. 2002;3(5):298-302.
3. Rowlands MA, Gunnell D, Harris R, et al. Circulating insulin-like growth factor peptides and prostate cancer risk: a systematic review and meta-analysis. Int J Cancer. 2009;124(10):2416-2429.
4. Nimptsch K, Giovannucci E. Epidemiology of IGF-1 and Cancer, Insulinlike Growth Factors and Cancer: From Basic Biology to Therapeutics, Cancer Drug Discovery and Development. In: LeRoith D, ed. New York, N Y: Springer Science+Business Media, LLC; 2012:1-24.
5. Lin DW, FitzGerald LM, Fu R, et al. Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev. 2011;20(9):1928-1936.
6. Johansson M, McKay JD, Rinaldi S, et al. Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. Prostate. 2009;69(12):1281-1291.
7. Hunter DJ, Riboli E, Haiman CA, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer. 2005;5(12):977-985.
8. Gu F, Schumacher FR, Canzian F, et al. Eighteen insulin-like growth factor pathway genes, circulating levels of IGF-I and its binding protein, and risk of prostate and breast cancer. Cancer Epidemiol Biomarkers Prev. 2010; 19(11):2877-2887.
9. Packer BR, Yeager M, Burdett L, et al. SNP500Cancer: a public resource for sequence validation, assay development, and frequency analysis for genetic variation in candidate genes. Nucleic Acids Res. 2006;34(database issue):D617-D621.
10. Li Y, Willer C, Sanna S, et al. Genotype imputation. Annu Rev Genomics Hum Genet. 2009;10:387-406.
11. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst. 2002;94(14):1099-1106.
12. Platz EA, Pollak MN, Leitzmann MF, et al. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes Control. 2005;16(3):255-262.
13. Weiss JM, Huang WY, Rinaldi S, et al. IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Int J Cancer. 2007;121(10):2267-2273.
14. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res. 2003;63(14):3991-3994.
15. Allen NE, Key TJ, Appleby PN, et al. Serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1121-1127.
16. Rosner B. Percentage points for a generalized esd many-outlier procedure. Technometrics. 1983;25(2):165-172.
17. Lin X, Cai T, Wu MC, et al. Kernel machine SNP-set analysis for censored survival outcomes in genome-wide association studies. Genet Epidemiol. 2011;35(7):620-631.
18. Cai T, Tonini G, Lin X. Kernel machine approach to testing the significance of multiple genetic markers for risk prediction. Biometrics. 2011;67(3):975-986.
19. Shui IM, Mucci LA, Kraft P, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012;104(9):690-699.
20. Liu CY, Wu MC, Chen F, et al. A large-scale genetic association study of esophageal adenocarcinoma risk. Carcinogenesis. 2010;31(7):1259-1263.
21. Gao X, Starmer J, Martin ER. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet Epidemiol. 2008;32(4):361-369.
22. Fine J P, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
23. Schumacher FR, Cheng I, Freedman ML, et al. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010; 19(15):3089-3101.
24. Eeles RA, Kote-Jarai Z, Al Olama AA, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet. 2009;41(10):1116-1121.
25. Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999;19(5):3278-3288.
26. Okutsu T, Kuroiwa Y, Kagitani F, et al. Expression and imprinting status of human PEG8/IGF2AS, a paternally expressed antisense transcript from the IGF2 locus, in Wilms' tumors. J Biochem. 2000;127(3):475-483.
27. Ogawa O, Eccles MR, Szeto J, et al. Relaxation of insulin-like growth factor-II gene imprinting implicated in Wilms tumor. Nature. 1993;362(6422):749-751.
28. Murphy SK, Huang Z, Wen Y, et al. Frequent IGF2/H19 domain epige-netic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol Cancer Res. 2006;4(4):283-292.
29. Nakagawa H, Chadwick RB, Peltomaki P, et al. Loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci USA. 2001;98(2):591-596.
30. Bhusari S, Yang B, Kueck J, et al. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer. Prostate. 2011;71(15):1621-1630.
31. Hendrickson AW, Haluska P. Resistance pathways relevant to insulinlike growth factor-1 receptor-targeted therapy. Curr Opin Invest Drugs. 2009;10(10):1032-1040.
32. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocrine Rev. 2003;24(4):389-427.
33. Halmos G, Schally AV, Sun BD, et al. High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metabolism. 2000;85(7):2564-2571.
34. Plonowski A, Schally AV, Nagy A, et al. Inhibition of PC-3 human andro-gen-independent prostate cancer and its metastases by cytotoxic somato-statin analogue AN-238. Cancer Res. 1999;59(8):1947-1953.
35. Barcena DG, Schally AV, Buenfil M V, et al. Response of patients with advanced prostatic cancer to administration of somatosta-tin analog RC-160 (vapreotide) at the time of relapse. Prostate. 2003;56(3):183-191.